Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-11-25
2000-12-12
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514810, 514811, 514813, 514812, A61K 3155
Patent
active
061599638
DESCRIPTION:
BRIEF SUMMARY
This invention provides a method for using 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, (hereinafter referred as "olanzapine"), for the treatment of dependence on a controlled substance. The present method provides a method for helping the patient to want to stop taking the drug, lessen the adverse symptoms of withdrawal from the drug and to minimize the relapse into abuse of the drug.
As long as history has been recorded, every society has used drugs that alter mood, thought, and feeling. In addition, pharmacological advances sometimes have been paralleled by physical as well as unfortunate behavioral dependence on agents initially consumed for therapeutic purposes. Therefore, the alleviation and eventual withdrawal from undesired physical and psychological dependence and tolerance of a substance has been a challenge throughout history. Although there are some treatments available for such withdrawal from addictive and/or mind altering substances, there is a great need for safer and more effective treatments.
It would be particularly desired to provide an effective treatment that could minimize hospitalization or institutionalization of a patient. The treatment must be non-addictive and provide a favorable side effect profile. It is particularly desired to provide a method that can help the patient want to stop taking the substance and ease the withdrawal effects when the patient stops taking the undesired substance. It is especially desired if the method minimizes the instances of relapse into abuse of the substance. Applicants believe that olanzapine could fulfill these needs.
It is known that olanzapine can provide antipsychotic activity. Olanzapine is a known compound and described in U.S. Pat. No. 5,229,382 as being useful for the treatment of schizophrenia, schizophreniform disorder, acute mania, mild anxiety states, and psychosis. U.S. Pat. No. 5,229,382 is herein incorporated by reference in its entirety. Surprisingly, and in accordance with this invention, Applicants have discovered that olanzapine can be useful for the treatment of substance abuse and withdrawal from such undesired physically and/or psychologically addictive substances.
The presently claimed invention provides a method for treating a condition which is a response produced by cessation and withdrawal from the abuse of a substance which is physically and/or psychologically addictive, comprising administering an effective amount of olanzapine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
This invention further provides a method for treating substance abuse comprising administering an effective amount of olanzapine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
This invention provides a method for treating dependence on a mind, thought or mood altering substance comprising administering an effective amount of olanzapine or a pharmaceutically acceptable salt thereof to a patient in need of or desiring such treatment.
This invention provides a method for assisting the patient to want to stop taking the mind, thought or mood altering substance. Further, this invention provides a method for easing the adverse withdrawal effects when the patient stops taking the undesired substance. Finally, this invention provides a method to minimize the instances of relapse into abuse of the substance.
Said substances include, but are in no way limited to opioids, anxiolytic and hypnotic drugs, cocaine, psychedelic agents, marijuana, amphetamines, hallucinogens, phencyclidine, and benzodiazepines. Said substances further include alcohol.
Finally, the present invention provides a method for treating alcohol withdrawal syndrome comprising administering an effective amount of olanzapine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
Olanzapine is of the formula ##STR1## or an acid addition salt thereof.
It is especially preferred that olanzapine will be the Form II olanzapine polymorph having a typical x-ray p
REFERENCES:
patent: 5229382 (1993-07-01), Chakrabarti et al.
patent: 5605897 (1997-02-01), Beasley, Jr. et al.
patent: 5605911 (1997-02-01), Olney et al.
patent: 5696115 (1997-12-01), Rasmussen
Carlton K. Erickson, Alcohol & Alcoholism, 31 Suppl. 1:5-11, Mar. 1996.
Minzhang, et al., World Health Forum, 16(I): 1-9, discussion Oct. 27, 1995.
Beasley Charles M
Rasmussen Kurt
Tollefson Gary D
Eli Lilly and Company
Harrison Nancy J
Palmberg Arleen
Vorndran-Jones MaCharri
Weddington Kevin E.
LandOfFree
Method for treating substance abuse does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating substance abuse, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating substance abuse will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-217285